Showing session: reset
Can the Challenge of NSCLC Resistance Be MET or Will We Not MEK It?
- Sort by:
 
- Browse by:
 
- Permission not
granted for presentation 
Preliminary efficacy and safety results of savolitinib treating patients with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations
              Shun Lu
              Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China
      - Free
 - slides video
 - audio + slides
 - All slides included
 
TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-amplified NSCLC after progression on prior epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)
              Lecia Sequist
              Massachusetts General Hospital, Boston, MA, United States
      - Free
 - slides video
 - audio + slides
 - All slides included
 
Osimertinib plus selumetinib for patients (pts) with EGFR-mutant (EGFRm) NSCLC following disease progression on an EGFR-TKI: Results from the Phase Ib TATTON study
              Suresh S Ramalingam
              Emory Univ. Winship Cancer Inst., Atlanta, GA, United States
      - Free
 - slides video
 - audio + slides
 - All slides included
 
Discussant
              Roy S Herbst
              Yale Cancer Ctr., New Haven, CT, United States
      
